Organogenesis
This article was originally published in The Gray Sheet
Executive Summary
Return of Apligraf bi-layered, living skin substitute to the market will be sought under a chapter 11 bankruptcy reorganization plan filed Sept. 25 in Boston federal court. An exclusive distribution pact with Novartis was terminated earlier this month when the parties failed to agree on an amended arrangement (1"The Gray Sheet" Sept. 16, 2002, In Brief). The Canton, Massachusetts firm's workforce was subsequently cut from 125 to 15...
You may also be interested in...
Organogenesis revived
Re-privatized maker of Apligraf living skin substitute will unveil a 15-20 person sales force in January, with plans to achieve profitability by February - six months after emerging from Chapter 11 bankruptcy. No additional capital will be needed to reach that milestone, the firm reports, due to funding from a group of six investors led by Chairman and CEO Alan Ades. The firm filed for Chapter 11 in 2002 to escape an exclusive marketing agreement with Novartis (1"The Gray Sheet" Sept. 30, 2002, In Brief). Having jettisoned its FortaFlex rotator cuff repair patch and other products, the 80-employee firm will focus mainly on selling Apligraf to treat diabetic foot ulcers and venous leg ulcers...
Organogenesis Apligraf
Novartis Pharma is set to resume shipments of the bi-layered, living skin substitute under an agreement announced Nov. 20. Novartis suspended its distribution in September after the companies failed to agree on an amended arrangement ("1The Gray Sheet" Sept. 30, 2002, In Brief). Under the new arrangement, the licensing and distribution rights to Apligraf will revert to Organogenesis in June 2003. Subject to approval of a Boston bankruptcy court, the deal is part of a Chapter 11 reorganizing plan filed by Organogenesis in September...
Organogenesis
Shipments of Apligraf bi-layered, living skin substitute to Novartis Pharma AG will be suspended until the two firms can reach an "equitable resolution" over how to restructure their supply arrangement. The companies have been in discussions since July over amending the relationship; however, no agreement has been reached and talks are ongoing (1"The Gray Sheet" July 15, 2002, p. 15). As a result of the halted shipments, Organogenesis will place 110 of its employees on furlough for up to two weeks until a resolution is met...